Oppenheimer analyst Steven Lichtman raised the firm’s price target on Boston Scientific (BSX) to $118 from $110 and keeps an Outperform rating on the shares. The firm says that Q2 sales of $5.06B beat its/Street’s $4.9B estimates and EPS of 75c were ahead its/Street’s 73c, led by the revenue beat, partially offset by ACURATE inventory charges following the May decision to discontinue the platform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $123 from $117 at Baird
- Boston Scientific price target raised to $135 from $130 at UBS
- Boston Scientific price target raised to $124 from $118 at Wells Fargo
- Boston Scientific price target raised to $133 from $125 at Barclays
- Boston Scientific Reports Strong Q2 2025 Results